Get the Stockscreener App
27.87
4.79%
-1.37
Pulse Biosciences Inc stock is traded at $27.87, with a volume of 184.58K.
It is down -4.79% in the last 24 hours and up +11.36% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
See More
Previous Close:
$29.24
Open:
$29.03
24h Volume:
184.58K
Relative Volume:
0.56
Market Cap:
$1.93B
Revenue:
$751.00K
Net Income/Loss:
$-74.57M
P/E Ratio:
-25.27
EPS:
-1.1031
Net Cash Flow:
$-55.52M
1W Performance:
+7.28%
1M Performance:
+11.36%
6M Performance:
+103.21%
1Y Performance:
+84.49%
1-Day Range:
$27.71
$29.03
1-Week Range:
$25.31
$31.00
52-Week Range:
$12.56
$31.00
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, MDLN, ALC, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
27.87 | 1.97B | 751.00K | -74.57M | -55.52M | -1.1031 |
ISRG
Intuitive Surgical Inc
|
397.62 | 143.33B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
151.32 | 42.96B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
39.40 | 32.87B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
67.13 | 33.07B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
194.90 | 29.05B | 5.54B | 1.52B | 1.74B | 10.37 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | Mizuho | Outperform |
| Jul-07-25 | Initiated | Oppenheimer | Outperform |
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
Price to sales forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Price to book forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Enterprise value to EBIT forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Price to book forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Enterprise value to revenue forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Enterprise value to revenue forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Price to sales forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Price to earnings forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Pulse Biosciences Inc (PLSE) Institutional Confidence - TradingKey
Pulse Biosciences stock hits 52-week high at $28.68 - Investing.com
Pulse Biosciences stock hits 52-week high at $28.68 By Investing.com - Investing.com UK
Pulse Biosciences, Inc. Actuals & Estimates (NASDAQ:PLSE) - TradingView
Pulse Biosciences, Inc. Actuals & Estimates (DUS:6L8) - TradingView
6L8 Forecast — Price Target — Prediction for 2027 - TradingView
Pulse Biosciences Inc (PLSE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth - Moomoo
Pulse Biosciences Inc (PLSE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pulse Biosciences Inc (PLSE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pulse Biosciences (PLSE) Is Up 5.0% After Joining S&P Healthcare Equipment Index Is Sentiment Shifting? - simplywall.st
Pulse Biosciences, Inc.(NasdaqCM:PLSE) added to S&P Healthcare Equipment Select Industry Index - marketscreener.com
Understanding Momentum Shifts in (PLSE) - Stock Traders Daily
Pulse Biosciences Stockweekly review and sector comparison - AD HOC NEWS
Pulse Biosciences Inc (PLSE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pulse Biosciences Inc (PLSE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pulse Biosciences Strengthens Executive Team - Medical Product Outsourcing
Pulse Biosciences Inc (PLSE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pulse Biosciences Inc (PLSE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pulse Biosciences Inc (PLSE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PLSE Q1 2026 Earnings: Narrower Loss Beats Expectations as Pulse Biosciences Advances CellFX PlatformRevenue Growth Outlook - dars.gov.et
What Could New Equity Awards Signal for Pulse Biosciences’ Ongoing Growth Efforts? - Kalkine Media
Pulse Biosciences (PLSE) director awarded stock options for 44,504 shares - Stock Titan
What Do Pulse Biosciences’ New Equity Awards Reveal About Executive Compensation Trends? - Kalkine Media
Director at Pulse Biosciences (NASDAQ: PLSE) receives new stock option grants - Stock Titan
[Form 4] PULSE BIOSCIENCES, INC. Insider Trading Activity - Stock Titan
Pulse Biosciences Plunges Over 9% as Selling Pressure Intensifies, Key Support in PlayHigh Low Breadth - newsline.com
Pulse Bio to redeem remaining common stock warrants - MSN
Pulse Biosciences Shareholders Approve Board and Auditor Slate - TipRanks
Pulse Biosciences (PLSE) investors back all directors and Deloitte as 2026 auditor - Stock Titan
Pulse Biosciences (PLSE) Hovers Near Resistance After Modest GainVolume Breadth - newsline.com
Pulse Biosciences Stock (US73242P1030): Shares in focus after recent conference appearance - AD HOC NEWS
Pulse Biosciences (PLSE) upgraded to buy: What does it mean for the stock? - MSN
Pulse Biosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
Pulse Biosciences (PLSE) Surges 7.6% on Increased Volume, Testing Key ResistanceSynthetic Short - newsline.com
PLSE: Directors and auditor ratified as company advances AFib trial and strengthens leadership - TradingView
Pulse Biosciences Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Pulse Biosciences (PLSE) to Redeem Outstanding Warrants by June 2026 - GuruFocus
PLSE: Nanosecond PFA platform shows high efficacy in AFib, with FDA approval targeted for late 2027 - TradingView
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants - Investing News Network
Pulse Bio to redeem common stock warrants (PLSE:NASDAQ) - Seeking Alpha
Pulse Biosciences Announces Redemption of Remaining 200% Warrants - TipRanks
Pulse Biosciences to redeem remaining warrants after VWAP triggers; exercise window until July 13, 2026 - TradingView
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pulse Biosciences Inc Stock (PLSE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Director |
May 11 '26 |
Buy |
19.69 |
660,233 |
12,999,988 |
48,211,433 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Option Exercise |
1.53 |
5,000 |
7,650 |
48,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Sale |
23.63 |
20,000 |
472,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Sale |
23.53 |
20,000 |
470,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Sale |
23.37 |
20,000 |
467,400 |
43,298 |
3.02%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):